Roche Holding AG Bearer Shares RO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RO is a good fit for your portfolio.
News
-
Roche ramps up obesity-drug competition with early-stage trial results
-
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial — Update
-
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
-
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
-
Roche prepares for business after boom from COVID-related products
-
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
-
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
-
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Trading Information
- Previous Close Price
- CHF 256.80
- Day Range
- CHF 255.60–259.80
- 52-Week Range
- CHF 229.40–318.00
- Bid/Ask
- CHF 260.00 / CHF 260.00
- Market Cap
- CHF 205.85 Bil
- Volume/Avg
- 24,497 / 33,937
Key Statistics
- Price/Earnings (Normalized)
- 13.18
- Price/Sales
- 3.43
- Dividend Yield (Trailing)
- 3.72%
- Dividend Yield (Forward)
- 3.72%
- Total Yield
- 3.72%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.18 | 60.45 | 15.00 |
Price/Book Value | 7.02 | 8.23 | 36.24 |
Price/Sales | 3.43 | 5.44 | 5.35 |
Price/Cash Flow | 12.63 | 19.13 | 15.49 |
Price/Earnings
RO
MRK
ABBV
Financial Strength
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.99 | 0.68 | 0.72 |
Current Ratio | 1.35 | 1.25 | 0.94 |
Interest Coverage | 14.93 | 3.97 | 3.95 |
Quick Ratio
RO
MRK
ABBV
Profitability
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 17.03% | 5.22% | 14.14% |
Return on Equity (Normalized) | 53.42% | 13.56% | 172.29% |
Return on Invested Capital (Normalized) | 26.30% | 8.29% | 27.87% |
Return on Assets
RO
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Dxfnxbjpy | Jpm | $732.9 Bil | |
JNJ
| Johnson & Johnson | Zzpxfbvr | Wftq | $372.2 Bil | |
MRK
| Merck & Co Inc | Wrbbnxnv | Mfc | $332.3 Bil | |
ABBV
| AbbVie Inc | Zphyclzk | Pgzq | $290.2 Bil | |
AZN
| AstraZeneca PLC ADR | Dcjthsqlph | Mcnk | $237.9 Bil | |
RHHBY
| Roche Holding AG ADR | Pqdzhqvmb | Mglk | $211.1 Bil | |
NVS
| Novartis AG ADR | Xzzbyww | Zqp | $210.2 Bil | |
AMGN
| Amgen Inc | Kpxtngbv | Qqcs | $167.6 Bil | |
PFE
| Pfizer Inc | Pfxzlgkh | Jrvs | $162.3 Bil | |
SNY
| Sanofi SA ADR | Rxbxwby | Xgy | $121.1 Bil |